9 research outputs found

    Electrochemical Carbon Dioxide Capture and Concentration

    No full text
    Electrochemical carbon capture and concentration (eCCC) offers a promising alternative to thermochemical processes as it circumvents the limitations of temperature-driven capture and release. This review will begin by discussing the history of eCCC, describing early work in the field and the motivation for pursuing such a process. We will then transition towards discussing more recent approaches, with a heavier emphasis on methods that employ redox mediators to facilitate CO2 capture and release. These methods rely more on optimization through chemical design and include pH-mediated systems, electrochemically-mediated amine regeneration, and direct capture with redox-active molecules. For each approach, we provide a general overview of the system, discuss redox mediator chemistries that have been studied in literature, and highlight requirements for future generations of redox mediators. We also describe previous demonstrations of each method and current cell/system designs that have been used at the lab-scale. To conclude, we summarize achievements in the field, current challenges, and opportunities for improving these technologies. Overall, this review is a comprehensive survey of the eCCC field and evaluates the chemical, theoretical, and electrochemical engineering aspects of this approach. We hope this work can be used to assist the community in the development of modern economical eCCC technologies that can be utilized in large-scale CCS processes

    Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators

    No full text
    BACKGROUND: Current modulator therapies for some cystic fibrosis-causing CFTR mutants, including N1303K, have limited efficacy. We provide evidence here to support combination potentiator (co-potentiator) therapy for mutant CFTRs that are poorly responsive to single potentiators. METHODS: Functional synergy screens done on N1303K and W1282X CFTR, in which small molecules were tested with VX-770, identified arylsulfonamide-pyrrolopyridine, phenoxy-benzimidazole and flavone co-potentiators. RESULTS: A previously identified arylsulfonamide-pyrrolopyridine co-potentiator (ASP-11) added with VX-770 increased N1303K-CFTR current 7-fold more than VX-770 alone. ASP-11 increased by ~65% of the current of G551D-CFTR compared to VX-770, was additive with VX-770 on F508del-CFTR, and activated wild-type CFTR in the absence of a cAMP agonist. ASP-11 efficacy with VX-770 was demonstrated in primary CF human airway cell cultures having N1303K, W1282X and G551D CFTR mutations. Structure-activity studies on 11 synthesized ASP-11 analogs produced compounds with EC50 down to 0.5â€ŻÎŒM. CONCLUSIONS: These studies support combination potentiator therapy for CF caused by some CFTR mutations that are not effectively treated by single potentiators
    corecore